Quarterly Result5 Aug 2025, 04:14 pm
Welcure Drugs & Pharmaceuticals Reports 830% Q-o-Q Net Profit Rise in QIFY26, Earns Rs 23.29 Crore
AI Summary
Welcure Drugs & Pharmaceuticals Ltd has announced its financial results for the quarter ended June 30, 2025 (QIFY26), revealing a robust performance driven by its strategic foray into fee-based, export-oriented sourcing services. The company's revenue from operations rose sharply to Rs 299.91 crores, up from Rs 21.21 crores in the previous quarter. The company reported a net profit of Rs 23.29 crores, a significant increase from a net loss of Rs 0.34 crores in the same period last year. This represents an 830% rise in net profit on a Q-o-Q basis. The company's earnings per share (EPS) also improved, standing at Rs 2.07 in QIFY26 compared to Rs -0.26 in QIFY25.
Key Highlights
- Revenue from operations rose by about 1300% on a Q-o-Q basis to Rs 299.91 crores
- Net profit stood at Rs 23.29 crores, a significant increase from a net loss of Rs 0.34 crores in QIFY25
- This represents an 830% rise in net profit on a Q-o-Q basis
- The company recently completed seven export-sourcing assignments totalling Rs 299.91 crores
- Welcure had earlier secured a major Rs 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited